Recently, Rendu Biotech and India's renowned company, Green Apple Medical System, officially signed a strategic cooperation agreement in Shanghai. This collaboration marks a significant milestone in Rendu Biotech's international expansion. Leveraging their respective strengths, both parties will work together to promote the widespread adoption of RNA diagnostic technology in India and other markets. This partnership will contribute to the implementation of efficient and precise medical solutions while advancing the precision medicine industry towards greater intelligence and convenience.
Joining Forces to Expand the Global Market
In recent years, the global in vitro diagnostics market has maintained rapid growth. According to the latest market research report, the market size is expected to exceed $150 billion by 2030. As one of the fastest-growing healthcare markets worldwide, India has an increasing demand for high-precision and rapid diagnostic technologies. This collaboration aligns with this global trend, as both parties work together to advance the adoption of RNA diagnostic technology in India and Southeast Asia, providing innovative solutions for the global healthcare industry.
As a leading in vitro diagnostics company in China, Rendu Biotech has long been dedicated to the research and application of RNA diagnostic technology, holding a competitive edge in molecular diagnostics, product diversity, and clinical applications. Green Apple Medical System, on the other hand, has been deeply engaged in India's in vitro diagnostics industry for many years, boasting extensive market channels and professional localized service capabilities.
Deepening Collaboration for a Win-Win Future
This partnership will focus on product promotion, the development of a localized service system, and the introduction and expansion of RNA diagnostic technology-based products in the Indian market. Rendu Biotech will leverage Green Apple Medical System's extensive market channels in India to accelerate the market penetration of RNA diagnostic products and drive the localization and application of precision medical solutions. Meanwhile, Green Apple Medical System will benefit from Rendu Biotech's advanced technology, enhancing its competitiveness in India's in vitro diagnostics market.
Rendu Biotech Chairman Ju Jinliang stated, "RNA diagnostic technology is reshaping the global precision medicine landscape, while the demand for precise and efficient diagnostics continues to rise in India and Southeast Asia. This collaboration is a key step in Rendu Biotech's international strategy and will accelerate the transformation of medical technology innovations into practical applications."
Green Apple Medical System CEO Mr. Siva commented, "Rendu Biotech's strength in RNA diagnostic technology, combined with our deep market channels and operational expertise, will create a powerful synergy. We look forward to this partnership bringing more precise and efficient solutions to the in vitro diagnostics industry."
Empowering Industry Growth and Embracing New Opportunities
With the widespread adoption of precision medicine concepts and the rapid development of in vitro diagnostic technology, there is an increasing global demand for high-precision, rapid, and convenient diagnostic products.
In the future, Rendu Biotech will continue to deepen innovations in RNA diagnostic technology and expand into more healthcare markets through global collaborative models, accelerating the practical application of in vitro diagnostic technologies. Both parties look forward to using this collaboration as a starting point to jointly explore the intelligent development of precision medicine, promote its broader application, and support the industry's progress toward higher quality development.
Telephone · +86 021-50720200 Address · Building 15B, No. 528 Ruiqing Road, East District, Zhangjiang High tech Park, Shanghai
